Valued at USD 7.74 billion in 2024, the arrhythmia market is projected to reach USD 8.24 billion in 2025 and USD 14.59 billion by 2034, growing at a CAGR of 6.6% during the forecast period 2025–2034. Growth is driven by lifestyle factors such as smoking, excessive alcohol consumption and obesity, along with rising patient awareness. Key players include Applied Cardiac Systems, AliveCor, Biotronik, Biotricity, GE Healthcare, iRhythm Technologies, Koninklijke Philips N.V., Medtronic plc., Nihon Kohden Corporation, St. Jude Medical (Abbott Laboratories), Spacelabs Healthcare (OSI Systems Inc.), and Welch Allyn (Hillrom Services Inc.). For B2B stakeholders, the arrhythmia market reflects strong demand for accurate, long-term diagnostic solutions.

Holter Monitor Leads Test Equipment Contribution

Within the test equipment segment, the Holter monitor segment is expected to be the most significant global revenue contributor during the forecast period. Holter monitors lead because they can be used for longer periods to diagnose sporadic symptoms. They also provide easier and faster monitoring, which improves patient compliance and treatment outcomes. The report points to the widespread use of the Holter monitor in long-term cardiac monitoring and early arrhythmia detection. Electrocardiogram equipment forms the other test equipment category, giving providers a defined choice of diagnostic pathways. The growing number of people suffering from the disorder, together with many advances in the cardiac monitoring devices sector, is driving the segment's growth.

Atrial Fibrillation Burden Supports Demand

The surge in cardiac arrhythmia cases is a primary growth driver. According to the National Institute of Health, atrial fibrillation affects 0.51% of the global population and has increased by 33% over the previous 20 years. The CDC identifies atrial fibrillation as the most frequent type of treated heart arrhythmia and expects it to affect 12.1 million people in the US by 2030. In 2019, it was noted on 183,321 death certificates. In the US, almost 454,000 hospitalizations each year have the condition as the primary diagnosis. More than 2 million people in the United Kingdom suffer from heart rhythm issues, according to a National Health Service report from September 2021. Every year, over 158,000 people die as a result of the disease, and the death rate from AFib as a major or contributory cause has been rising for more than two decades. It affects more women than men, since cases grow with age and women live longer than men.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/arrhythmia-market

Wearables and Next-Generation Cardiac Monitoring Devices

Increasing use of wearable ECG monitors and smart diagnostics is boosting demand, and advances in cardiac monitoring devices are supporting segment growth. Mobile cardiac outpatient telemetry is gaining popularity in the US. In January 2022, the US FDA awarded Biotricity's Biotres Cardiac Monitoring Device 510(k) certification for ECG monitoring. The device is a wearable Holter patch that continuously records ECG data in three channels. In May 2024, Vivalink unveiled a platform combining mobile cardiac telemetry and Holter monitoring with advanced arrhythmia detection, aimed at simplifying deployment and lowering operational costs in ambulatory ECG monitoring services. This has helped the company expand its cellular device product offering in the US.

Regional Highlights and Market Constraints

North America had the largest revenue share in 2024, supported by advanced healthcare infrastructure and rising adoption of diagnostic technologies. Asia Pacific is expected to witness a high CAGR, driven by rising healthcare investments and a growing elderly population, with China and India described as hotspots for investment potential. The report also cites constraints, including difficulties associated with devices and an increase in arrhythmia monitoring device recalls, which could adversely influence the market. High cost of treatment is listed among the restraints in the report's table of contents.

Conclusion

The arrhythmia market is supported by a rising disease burden, technology-led diagnostics and expanding wearable adoption. Companies that strengthen device reliability and long-term monitoring capabilities are well placed to capture opportunities through 2034. Industry developments such as new remote patient monitoring platforms show that vendors are prioritizing simplified deployment and improved patient management.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market